Targeted Therapies Compared to Dacarbazine for Treatment of BRAF^V600E Metastatic Melanoma: A Cost-Effectiveness Analysis

Figure 2

(a) Kaplan-Meier Overall Survival Curve. (b) Kaplan-Meier Progression-Free Survival Curve. (The probabilities from 0–8 months are from clinical trial data. The probabilities from 8 months to end of life are modeled using the DEALE method.)

(a)

(b)